<DOC>
	<DOCNO>NCT00279110</DOCNO>
	<brief_summary>The purpose study determine whether provide directly administer antiretroviral therapy HIV-infected receive methadone therapy lead well treatment outcome take HIV medication .</brief_summary>
	<brief_title>Directly Administered HIV Therapy Methadone Clinics</brief_title>
	<detailed_description>We propose conduct randomize , unblinded , clinical trial medication adherence intervention opioid-dependent , HIV-infected participant initiate new antiretroviral therapy , receive opioid agonist maintenance therapy methadone buprenorphine opioid treatment program ( OTPs ) Baltimore , MD . Randomization stratify study site prior antiretroviral exposure . Two hundred participant randomly assign 1:1 self-administered antiretroviral therapy ( SAT ) directly administer antiretroviral therapy ( DAART ) . Subjects assign DAART take morning dos antiretroviral therapy nurse medical assistant private room OTP . DAART subject transfer self-administered therapy 12 month . This 5 year study participant enrol month 6 month 42 study . The maximum follow-up individual participant 18 month . Based pilot experience anticipate 50 % subject woman , 80 % African American , median age 44 year . The following outcome compare two study arm : - Suppression viral load ( primary outcome ) - Changes CD4+ cell count - The development antiretroviral drug resistance - Retention opioid agonist maintenance therapy , urine toxicology screen drug abuse , self-reported drug alcohol use - Self-reported adherence therapy , retention ART , clinical psychosocial moderator adherence - Electronically monitor medication adherence , use MEMS cap , first 2 month study Outcomes data obtain study assessment visit baseline , 3 month , 6 month , 12 month , 18 month . Participants provide contact information , take interviewer-administered survey , provide blood urine sample study assessment visit . MEMS cap data capture 1 month 2 month . Subjects compensate successful completion study assessment visit MEMS interrogation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>1 . Eighteen year age old 2 . Documented serologic evidence HIV infection ( positive ELISA Western blot ) 3 . Identifiable medical provider , responsible manage HIV treatment 4 . Proof ART prescribe patient prescription medication coverage 5 . Nadir CD4+ cell count &lt; 350/mm3 offtreatment HIV RNA &gt; 55,000 copies/ml asymptomatic ART naive 6 . Current plasma HIV RNA &gt; 500 copies/ml 7 . Initiating ART first time , reinitiating therapy stopping , change therapy due virologic failure 8 . ART least 3 agent , include protease inhibitor , nonnucleoside reverse transcriptase inhibitor , abacavir 9 . Methadone buprenorphine maintenance therapy &gt; 3 week , plan detoxification 1 . Need use ART dose frequently twice daily , 2 . Need use liquid preparation antiretroviral medication , 3 . Documented tripleclass antiretroviral resistance ( define ) , 4 . Participation another study program include directly observe therapy . 5 . Use ART regimens expressly discourage DHHS HIV clinical care guideline Tripleclass antiretroviral resistance define accord IASUSA interpretive guideline : NRTI class 3 thymidine nonthymidineassociated mutation ( exclude M184V mutation ) multinucleoside resistance mutation reverse transcriptase ; PI class 3 protease mutation , include 1 primary mutation ; NNRTI class 1 primary ( K103N Y188L ) 2 secondary NNRTIassociated mutation reverse transcriptase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>Heroin dependence</keyword>
	<keyword>Methadone</keyword>
	<keyword>Buprenorphine</keyword>
</DOC>